Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results

Purpose: Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma. To confirm these promising results, we conducted a phase II prospective study. Patients and Methods: Sixty-three patients with histologic confirmation of recurrent glioma were treated with the MOP regimen, Patients with or without prior chemotherapy received nitrogen mustard 3 mg/m(2) or 6 mg/m(2), respectively, intravenously on days 1 and 8 plus vincristine 2 mg/m(2) intravenously on days 1 and 8, and procarbazine 100 mg/m(2) orally on days 1 to 14. Cycles were repeated every 28 days, Results: Of 61 patients assessable for response, eight responded (13%), with one complete response (CR), Responses were as follows: low-grade gliomas, 19%; anaplastic astrocytomas, 11%; anaplastic oligodendrogliomas or oligoastrocytomas, 25%; and glioblastomas, 4.3%, The most common toxicity was myelosuppression with leukocyte nadirs less than 1,000/mu L in 23% and platelet nadirs less than 25,000/mu L in 13% of patients. Two patients died of infection in the setting of neutropenia, Nonhematologic toxicity included neurosensory changes in 21% of patients (severe in 3%) and severe dermatologic reactions in 8%. In multivariate analysis, Eastern Cooperative Oncology group (ECOG) performance status (PS) was the best predictor for response to chemotherapy (P = .01) and time to progression (P = .008), while PS and grade were the most important predictors of survival (P = .002 and .05, respectively). Conclusion: This study did not confirm the high response rate previously reported in recurrent gliomas. Patients with recurrent anaplastic oligodendrogliomas or oligoastrocytomas and recurrent low-grade gliomas had the highest response rates (25% and 19%, respectively), In multivariate analysis, ECOG PS was the best predictor of response, while PS and tumor grade were the most important predictors of survival. J Clin Oncol 16:2953-2958. (C) 1998 by American Society of Clinical Oncology.